Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Newave Pharmaceutical Inc
City of Hope Medical Center
MacroGenics
City of Hope Medical Center
City of Hope Medical Center
Stanford University
National Institutes of Health Clinical Center (CC)
University of California, Davis